The myocardium contains collagen matrix that is a major determinant of its architecture, structural integrity, and mechanical properties. This fibrillar matrix consists primarily of type I and type III collagens having epimysial, perimysial, and endomysial components. The present study shows the alteration of collagen phenotypes during the evolution of hypertensive hypertrophy. Therapy with captopril, an angiotensin-converting enzyme inhibitor that regresses cardiac hypertrophy, not only reduces the total amount of collagen but reverses the altered distribution of type I and type III collagen. In normotensive rats, captopril did not significantly reduce collagen content or alter the ratio of type I to type III collagen. (Circulation Research 1990;67:1474-1480 C ollagen is responsible for the functional integrity of the myocardium, which allows interdigitation and transmission of force between contracting myocytes. The collagen network in the heart is largely influenced by the load. Collagen has been shown to be synthesized in the heart primarily by fibroblasts.1'2 It has been reported that pressure overload increases the collagen content within the left ventricular myocardium. Furthermore, evidence suggests that collagen probably plays a role in the stress-strain relation within the left ventricular myocardium during diastole and, perhaps, during systole.34 Bing et a15 noted that the velocity of shortening of hypertrophied left ventricular columnae carneae cordis muscles was reduced. In humans, it is recognized that the diastolic function of the hypertrophied pressure-overloaded myocardium and, in particular, early ventricular filling will be compromised.6 Various investigators have determined that, in pressure overload hypertrophy, there is a higher hydroxyproline content,7 and this may lead to the development of increased resting tension.7 But myocardial stiffness may be independent of collagen content. rise in the stress-strain relation of the left ventricle. Forty weeks after surgery, there was a 32% increase in collagen content, but a very small change in stress-strain relation. These findings suggest that ventricular compliance may be related to some other parameter, such as the type of collagen present. Jalil et al9 used picrosirius red and polarization microscopy to monitor the transformation of the collagen matrix during cardiac hypertrophy. Perhaps this technique is inadequate for quantification of collagen phenotypes, because differential coloration is not due to specific interaction between sirius red and types I and III collagen but to the normal difference in diameter. Because type III frequently remains associated with type I, this method cannot quantify or distinguish type I from type III collagen.
C ollagen is responsible for the functional integrity of the myocardium, which allows interdigitation and transmission of force between contracting myocytes. The collagen network in the heart is largely influenced by the load. Collagen has been shown to be synthesized in the heart primarily by fibroblasts.1'2 It has been reported that pressure overload increases the collagen content within the left ventricular myocardium. Furthermore, evidence suggests that collagen probably plays a role in the stress-strain relation within the left ventricular myocardium during diastole and, perhaps, during systole. 34 Bing et a15 noted that the velocity of shortening of hypertrophied left ventricular columnae carneae cordis muscles was reduced. In humans, it is recognized that the diastolic function of the hypertrophied pressure-overloaded myocardium and, in particular, early ventricular filling will be compromised.6 Various investigators have determined that, in pressure overload hypertrophy, there is a higher hydroxyproline content,7 and this may lead to the development of increased resting tension.7 But myocardial stiffness may be independent of collagen content. Thiedemann et a18 showed in Goldblatt hypertensive rats that at 4 and 8 weeks after surgery there is only a small increase in collagen content but a pronounced rise in the stress-strain relation of the left ventricle. Forty weeks after surgery, there was a 32% increase in collagen content, but a very small change in stress-strain relation. These findings suggest that ventricular compliance may be related to some other parameter, such as the type of collagen present.
Jalil et al9 used picrosirius red and polarization microscopy to monitor the transformation of the collagen matrix during cardiac hypertrophy. Perhaps this technique is inadequate for quantification of collagen phenotypes, because differential coloration is not due to specific interaction between sirius red and types I and III collagen but to the normal difference in diameter. Because type III frequently remains associated with type I, this method cannot quantify or distinguish type I from type III collagen.
To quantify collagen phenotypes, another important issue to consider is solubility of cardiac collagen. Most of the reports available to date10 have used pepsin to extract collagen and quantify various types of collagen. Cardiac collagen is extremely insoluble and highly cross-linked, especially during the chronic phase of myocardial hypertrophy.1" The present paper describes quantitation of collagen phenotypes using cyanogen bromide to solubilize collagen and the effect of captopril, a very commonly used antihypertensive agent, on collagen content and phenotype.
Materials and Methods

Study Groups
All spontaneously hypertensive rats (SHRs) used in this study were American Wistar (Wistar) rats, which were obtained from Hilltop Farm, Scottdale, Pa. Both normotensive and hypertensive rats were kept under the same conditions and were properly housed and fed with Purina rat chow. Arterial pressure was measured using a tail cuff in a method similar to that described by Sen and Bumpus.12 In all experiments, rats were killed after anesthetizing with ether, and ventricles were cut flush with the surface to remove aortic tissue and were cleaned thoroughly with phosphate buffered saline (PBS) to remove all traces of blood. The left ventricle then was separated from the right ventricle and atrial tissue. The left ventricular tissue was used for all experiments.
Deternination of Hydroxyproline
The amount of hydroxyproline in this tissue was determined by using a modified Stagemann procedure. 13 Myocardial tissue was homogenized, and hydrolysis of the sample solution was done with 6N HCl at 1100 C for 24 hours. The hydrolyzed samples were dried with a flash evaporator. Hydroxyproline standard solutions of 2, 4, 6, 8, and 10 ,ug/ml were made.
A reagent blank was included in the procedure by substituting water for the hydroxyproline solution, and absorbance was corrected accordingly. One-half milliliter hydroxyproline standard solutions of different strengths and homogenates of heart samples were taken in glass tubes, and 1 ml isopropanol was added. The tubes then were vortexed. To this solution, 0.5 ml of oxidant (0.35 g chloramine T plus 5 ml water plus 20 ml citrate buffer) was added, vortexed, and allowed to stand for 4 minutes. Three and one-fourth milliliters Ehrlich's reagent (3 ml Ehrlich's plus 16 ml isopropanol) subsequently was added. The tubes were kept at 250 C for 18 hours, and the intensity of red coloration was measured using a Beckman DU50 spectrophotometer (Beckman Instruments, Inc., Fullerton, Calif. 4 ,000g for 10 minutes. The supernatant, along with all subsequent supernatants, was retained so that proteins could be recovered by precipitation in 5% trichloroacetic acid. Next, the hydroxyproline content was determined. The residue was resuspended in 2% SDS and rehomogenized in the 10-ml glass homogenizer at room temperature. The homogenate again was centrifuged and rehomogenized in 2% SDS; the procedure was repeated four times. The remaining residue was further extracted three times with PBS to remove the excess SDS. The residue then was rehomogenized in acetone and centrifuged at 4,000g for 10 minutes; the supernatant was discarded. This step was repeated, and the pellet was dried under vacuum.
Digestion of collagen with cyanogen bromide. The acetone-dried powder was homogenized in an allglass homogenizer with 0.6 ml 70% vol/vol formic acid per 100 mg original tissue. The homogenate was transferred to a 15 -ml graduated polyethylene centrifuge tube, and any remaining residue was washed from the homogenizer with 0.6 ml formic acid. Homogenate was made up to a volume of 1.5 ml with 70% vol/vol formic acid per 100 mg original tissue. Cyanogen bromide crystals were added to this volume to produce a concentration of 20 mg/ml. Nitrogen gas then was bubbled through the mixture, tubes were sealed, and the reaction was allowed to proceed for 18 hours at 250 C. In our experiments, a digestion time of 18 hours was used because a 6-hour digestion, as recommended in the method of Laurent et al,14 could digest only 50% of the cardiac collagen. To facilitate mixing, the tubes were positioned at an angle of 300. At the completion of the reaction, the digest was centrifuged at 5,000g for 20 minutes. The stopper was removed in a fume cupboard, and 0.3 ml of the supernatant was removed and dried under vacuum in a 1.5 -ml microfuge tube. This material then could be dissolved in sample buffer in preparation for polyacrylamide gel electrophoresis. The amount to be loaded was determined by hydroxyproline estimation on the lyophilized powder obtained from 0.5 ml of supernatant. Collagen Typing Gel electrophoresis. Polyacrylamide gel electrophoresis was performed on vertical gels (Protean II, Bio-Rad Laboratories, Richmond, Calif.) by stacking and separating gel concentrations of 4% and 12%, respectively. The gels were 1.5 -mm thick, with 15 sample wells. Samples of a 10 -,l volume were loaded into the wells using a Hamilton microsyringe (Hamilton Co., Reno, Nev.), and stacking was allowed to occur at a current of 25 mA. Once the samples entered the separating gel, the current was increased to 35 mA, and electrophoresis continued until the dye marker reached a level two thirds from the top.
When electrophoresis was complete, the gel was removed and stained for 1 In 86-week-old SHRs, the collagen content was significantly higher in control animals (5.42±0.18 mg) as compared with captopril-treated animals (4.70+ 0.22 mg) ( Table 4 ). There was no significant difference in the collagen concentration between control rats (4.40±0.15 mg/g) and treated rats (4.80±0.32 mg/g) (Table 4) .
Collagen Phenotypes
Even though the collagen concentration did not show a significant difference between normotensive and hypertensive animals, there were marked changes in collagen phenotypes during evolution of hypertensive hypertrophy, as shown in Figure 3 . Ten-week-old SHRs had a significantly decreased type 1:111 ratio (1.83±0. 13 (Figure 3) .
At 86 weeks of age, there was a marked decrease in the type 1:111 ratio in SHRs (1.94±0.32,p<0.001) as compared with 34-week-old SHRs (10.31 ±0.69). Captopril treatment of this age group significantly increased the type 1:111 ratio to 3.12+ 0.69 (p<0.05) (Figure 3 ).
Discussion
It is now appreciated that the myocardium contains a collagen matrix that is a major determinant of its architecture, structural integrity, and mechanical properties.1' The collagen matrix of the heart consists primarily of type I and type III collagens. The interrelations among the structural features of these components, their biochemical characteristics and biophysical properties, and the function they serve in the myocardium have not been completely defined. Since Thiedemann et a18 showed that myocardial stiffness does not correlate with total collagen content, the possibility that the alteration of collagen phenotypes may be responsible for compromised function in hypertensive heart disease has been suggested.
Our study showed that myocardial collagen phenotype is perhaps more important than the total amount of collagen present in the myocardium. The dramatic decrease in the type 1:111 ratio in the established phase of hypertensive hypertrophy emphasizes that the type of collagen may play an important role in myocardial dysfunction. Many investigators10 have used pepsin to solubilize cardiac collagen to determine its phenotype. We have shown that pepsin could solubilize only about 12% of collagen. Any quantification based only on pepsin digestion is likely to be misleading. In our studies, we used cyanogen bromide, which solubilized about 82-88% of collagen. This is in agreement with the studies of Laurent et al,14 who used cyanogen bromide to extract collagen from lung tissue.
To elucidate how hypertensive hypertrophy affected the collagen in the heart, the total collagen content, collagen concentration, and the ratio of type 1:111 collagen were determined. In agreement with other investigators," we found that the collagen concentration did not significantly differ from that of normal rats in hypertensive hypertrophy. It has been proposed that the elevation in resting tension is related to an abnormality in the collagen component in the heart. Because no significant alteration was evident in the collagen concentration, we hypothesized that the type of collagen, rather than the total amount, may play a more important role in determining myocardial function.
Based on our hypothesis, we determined the type I:111 ratio in 10-, 34-, and 86-week-old animals. In 10-week-old hypertensive rats, there was a significant increase in type III collagen, with a decrease in the type 1:111 ratio, in comparison with normotensive rats. This is in support of what Medugorac and Jacob10 reported in Goldblatt hypertensive and aortic stenotic rats. Our studies in 34-week-old normotensive animals showed a significant increase in type 1 collagen in comparison with 10-week-old normotensive rats, suggesting there is an increase in type I collagen with aging.
In 34-week-old hypertensive animals, there was a further significant increase in type I collagen in comparison with normotensive 34-week-old animals. In 86-week-old SHRs, however, there was a marked increase in type III collagen, with a sharp fall in the type 1:111 ratio. Bing et al16 have shown unequivocal myocardial dysfunction at 18 months, with normal cardiac function before that age group in spite of myocardial hypertrophy. We therefore decided to use 86-week-old hypertensive animals in our studies. Myocardial dysfunction during 18 months of age in SHRs has been documented in a number of studies.'7-20 The degree of myocardial dysfunction documented is variable, but almost all studies show some alteration in myocardial function, namely, prolonged electromechanical delay and time to peak tension. Pfeffer et al'7 demonstrated a marked decline in the peak pumping ability from 52 to 90 weeks of age in the SHR. Mirsky et al18 showed that in the normotensive rats, the myocardial stiffness constant remained within normal limits until 18 months. At this time, a significant increase in this index of myocardial stiffness occurred. They also showed that baseline and maximal cardiac indexes and ejection fraction index of SHRs were normal from 6 to 18 months but were markedly reduced at 
